rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-242-248rsp-3158Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL OBSERVATIONСтойкий эффект тоцилизумаба при рефрактерном артериите Такаясу (клиническое наблюдение)Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)https://orcid.org/0000-0001-5433-3300КойлубаеваГ. М.KoilubaevaG. M.

Койлубаева Гулазик Маликовна

720040, Бишкек, ул. Тоголока Молдо, 3

Gulazik M. Koilubaeva

720040, Bishkek, Togoloka Moldo str., 3

makmal@rambler.ruhttps://orcid.org/0000-0003-2172-9776СарыбаевА. Ш.SarybaevA. Sh.

720040, Бишкек, ул. Тоголока Молдо, 3

Akpay Sh. Sarybaev

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0003-1880-5678БолотбековаА. М.BolotbekovaA. M.

720040, Бишкек, ул. Тоголока Молдо, 3

Altynay M. Bolotbekova

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0002-1771-6246ДубининаТ. В.DubininaT. V.

115522, Москва, Каширское шоссе, 34а

Tatiana V. Dubinina

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-4810-4875ДжузеноваФ. С.DzhuzenovaF. S.

720040, Бишкек, ул. Тоголока Молдо, 3

Fatima S. Dzhuzenova

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0002-5842-5066ЧукубаевМ. А.ChukubaevM. A.

720040, Бишкек, ул. Тоголока Молдо, 3

Zamirbek E. Turdukulov

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0002-7274-264XТурдукуловЗ. Э.TurdukulovZ. E.

720040, Бишкек, ул. Тоголока Молдо, 3

Zamirbek E. Turdukulov

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0002-0770-5121ДжайлобаеваК. А.DzhailobaevaK. A.

720000, Бишкек, ул. Киевская, 44

Klara A. Dzhailobaeva

720000, Bishkek, Kievskaya str., 44

Национальный центр кардиологии и терапии имени академика Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской РеспубликиКыргызстанNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicKyrgyzstanФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationГОУ ВПО Кыргызско-Российский Славянский университет имени Б.Н. ЕльцинаКыргызстанB.N. Yeltsin Kyrgyz-Russian Slavic UniversityKyrgyzstan202214052022602242248Copyright © Койлубаева Г.М., Сарыбаев А.Ш., Болотбекова А.М., Дубинина Т.В., Насонов Е.Л., Джузенова Ф.С., Чукубаев М.А., Турдукулов З.Э., Джайлобаева К.А., 20222022Койлубаева Г.М., Сарыбаев А.Ш., Болотбекова А.М., Дубинина Т.В., Насонов Е.Л., Джузенова Ф.С., Чукубаев М.А., Турдукулов З.Э., Джайлобаева К.А.Koilubaeva G.M., Sarybaev A.S., Bolotbekova A.M., Dubinina T.V., Nasonov E.L., Dzhuzenova F.S., Chukubaev M.A., Turdukulov Z.E., Dzhailobaeva K.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3158

Изучение роли интерлейкина 6 (ИЛ-6) в развитии хронического аутоиммунного воспаления привело к разработке инновационных методов лечения различных иммуновоспалительных ревматических заболеваний, в том числе артериита Такаясу (АТ). Учитывая важную роль ИЛ-6 в патогенезе АТ и его связь с высокой клинико-лабораторной активностью заболевания, тоцилизумаб (ТЦЗ) рекомендован в качестве препарата второй линии в случае неэффективности как глюкокортикоидов и базисных противовоспалительных препаратов, так и предшествующей терапии ингибиторами фактора некроза опухоли α. В статье представлено собственное наблюдение успешного применения ТЦЗ у пациентки с АТ рефрактерного течения.

Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association with high clinical and laboratory activity of the disease, tocilizumab (TCZ) is recommended as a second-line drug if both glucocorticoids and basic antiinflammatory drugs are inefficient, and previous therapy with tumor necrosis factor-α (alpha) inhibitors. The article presents our own observation of the successful use of TCZ in a patient with refractory TAK.

артериит Такаясуинтерлейкин 6воспалениетоцилизумабрефрактерностьактивностьстенозTakayasu’s arteritisinterleukin 6inflammationtocilizumabrefractorinessactivitystenosisИсследование не имело спонсорской поддержкиReferencesJennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715. PMID: 23045170Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715. PMID: 23045170Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: A review. J Clin Pathol. 2002;55(7):481-486. doi: 10.1136/jcp.55.7.481Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: A review. J Clin Pathol. 2002;55(7):481-486. doi: 10.1136/jcp.55.7.481Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009;48(8):1008-1011. doi: 10.1093/rheumatology/kep153Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009;48(8):1008-1011. doi: 10.1093/rheumatology/kep153Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89-99.Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89-99.Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11): 919-929. doi: 10.7326/0003-4819-120-11-199406010-00004Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11): 919-929. doi: 10.7326/0003-4819-120-11-199406010-00004Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu’s arteritis in Turkey – Clinical and angiographic features of 248 patients. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S59-S64.Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu’s arteritis in Turkey – Clinical and angiographic features of 248 patients. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S59-S64.Karageorgaki ZT, Bertsias GK, Mavragani CP, Kritikos HD, Spyropoulou-Vlachou M, Drosos AA, et al. Takayasu arteritis: Epidemiological, clinical, and immunogenetic features in Greece. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S33-S39.Karageorgaki ZT, Bertsias GK, Mavragani CP, Kritikos HD, Spyropoulou-Vlachou M, Drosos AA, et al. Takayasu arteritis: Epidemiological, clinical, and immunogenetic features in Greece. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S33-S39.Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical manifestations of Takayasu arteritis in India and Japan – New classification of angiographic findings. Angiology. 1997;48(5):369-379. doi: 10.1177/000331979704800501Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical manifestations of Takayasu arteritis in India and Japan – New classification of angiographic findings. Angiology. 1997;48(5):369-379. doi: 10.1177/000331979704800501Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. Circulation. 2015;132:17019. doi: 10.1161/CIRCULATIONAHA.114.012547Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. Circulation. 2015;132:17019. doi: 10.1161/CIRCULATIONAHA.114.012547Brunner J, Feldman BM, Tyrrell PN, Kuemmerle-Deschner JB, Zimmerhackl LB, Gassner I, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49(10):1806-1814. doi: 10.1093/rheumatology/keq167Brunner J, Feldman BM, Tyrrell PN, Kuemmerle-Deschner JB, Zimmerhackl LB, Gassner I, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49(10):1806-1814. doi: 10.1093/rheumatology/keq167Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? Circulation. 1999;100(1):55-60. doi: 10.1161/01.cir.100.1.55Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? Circulation. 1999;100(1):55-60. doi: 10.1161/01.cir.100.1.55Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45(5):545-548. doi: 10.1093/rheumatology/kei266Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45(5):545-548. doi: 10.1093/rheumatology/kei266Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, Direskeneli H. Serum cytokine profiles in Takayasu’s arteritis: Search for biomarkers. Clin Exp Rheumatol. 2015;33(2 Suppl 89): S32-S35.Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, Direskeneli H. Serum cytokine profiles in Takayasu’s arteritis: Search for biomarkers. Clin Exp Rheumatol. 2015;33(2 Suppl 89): S32-S35.Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353-1360. doi: 10.1002/art.39037Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353-1360. doi: 10.1002/art.39037Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016;34(3 Suppl 97): S21-S27.Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016;34(3 Suppl 97): S21-S27.Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi: 10.14412/1995-4484-2017-590-599Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-599 (In Russ.). doi: 10.14412/1995-4484-2017-590-599Насонов ЕЛ, Лила АМ, Чой Э. Второе поколение ингибиторов рецепторов интерлейкина 6 – новая веха в ревматологии. Эффективная фармакотерапия. 2019;15(23). URL: https://umedp.ru/articles/vtoroe_pokolenie_ingibitorov_retseptorov_interleykina_6_novaya_vekha_v_revmatologii_obshcherossiyski.html (Дата доступа: ##.##.2022)Nasonov EL, Lila AM, Choi E. The second generation of interleukin 6 receptor inhibitors is a new milestone in rheumatology. Effektivnaya farmakoterapia. 2019;15(23) (In Russ.). URL: https://umedp.ru/articles/vtoroe_pokolenie_ingibitorov_retseptorov_interleykina_6_novaya_vekha_v_revmatologii_obshcherossiyski.html (Дата доступа: ##.##.2022)Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58(4):1197-1200. doi: 10.1002/art.23373. PMID: 18383395Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58(4):1197-1200. doi: 10.1002/art.23373. PMID: 18383395Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumat, 2016;28:211-217. doi: 10.1097/BOR.0000000000000265Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumat, 2016;28:211-217. doi: 10.1097/BOR.0000000000000265Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37(4):578-582. doi: 10.1002/art.1780370420Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37(4):578-582. doi: 10.1002/art.1780370420Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasuэs arteritis. J Rheumatol. 2003;30(8):1793-1798.Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasuэs arteritis. J Rheumatol. 2003;30(8):1793-1798.Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007;26(11):1871-1875. doi: 10.1007/s10067-007-0596-zShinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007;26(11):1871-1875. doi: 10.1007/s10067-007-0596-zNakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J. 2013;54(6):405-411. doi: 10.1536/ihj.54.405Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J. 2013;54(6):405-411. doi: 10.1536/ihj.54.405Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, et al.; Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51(5):882-886. doi: 10.1093/rheumatology/ker380Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, et al.; Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51(5):882-886. doi: 10.1093/rheumatology/ker380Clifford A, Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: An update on use of biologic therapies. Curr Opin Rheumatol. 2014;26:7-15.doi: 10.1097/BOR.0000000000000004Clifford A, Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: An update on use of biologic therapies. Curr Opin Rheumatol. 2014;26:7-15.doi: 10.1097/BOR.0000000000000004Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, et al.; French Takayasu Network. Efficacy of biologicaltargeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/CIRCULATIONAHA.114.014321Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, et al.; French Takayasu Network. Efficacy of biologicaltargeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/CIRCULATIONAHA.114.014321Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64(7):1079-1083. doi: 10.1002/acr.21636Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64(7):1079-1083. doi: 10.1002/acr.21636Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129-1134. doi: 10.1002/art.1780330811Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129-1134. doi: 10.1002/art.1780330811Sharma BK, Jain S, Suri S, Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996;54(Suppl): S141-S147. doi: 10.1016/s0167-5273(96)88783-3Sharma BK, Jain S, Suri S, Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996;54(Suppl): S141-S147. doi: 10.1016/s0167-5273(96)88783-3Luqmani R. Evaluation of vasculitis disease activity in Europe. Eur J Intern Med. 2001;12(5):401-402. doi: 10.1016/s09536205(01)00158-3Luqmani R. Evaluation of vasculitis disease activity in Europe. Eur J Intern Med. 2001;12(5):401-402. doi: 10.1016/s09536205(01)00158-3Maksimowicz-McKinnon K, Clark T, Hoffman G. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum, 2007;56(3):10001009. doi: 10.1002/art.22404Maksimowicz-McKinnon K, Clark T, Hoffman G. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum, 2007;56(3):10001009. doi: 10.1002/art.22404Isobe M. Takayasu arteritis revisited: current diagnosis and treatment. Int J Cardiol. 2013;168:3-10. doi: 10.1016/j.ijcard.2013.01.022Isobe M. Takayasu arteritis revisited: current diagnosis and treatment. Int J Cardiol. 2013;168:3-10. doi: 10.1016/j.ijcard.2013.01.022Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O; Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev. 2013;12(12):11431149. doi: 10.1016/j.autrev.2013.06.019Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O; Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev. 2013;12(12):11431149. doi: 10.1016/j.autrev.2013.06.019Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720-1729. doi: 10.1002/acr.21750Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720-1729. doi: 10.1002/acr.21750Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51(1):151-156. doi: 10.1093/rheumatology/ker296Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51(1):151-156. doi: 10.1093/rheumatology/ker296Cañas CA, Cañas F, Izquierdo JH, Echeverri AF, Mejía M, Bonilla-Abadía F, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol. 2014;20(3): 125-129. doi: 10.1097/RHU.0000000000000098Cañas CA, Cañas F, Izquierdo JH, Echeverri AF, Mejía M, Bonilla-Abadía F, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol. 2014;20(3): 125-129. doi: 10.1097/RHU.0000000000000098Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5):536548. doi: 10.14412/19954484-2017-536-548Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. the authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-548 (In Russ.). doi: 10.14412/19954484-2017-536-548

The authors declare that there are no conflicts of interest present.